Market Intelligence, Clinical Progress, and High-Purity Reagents for Drug-Resistant RET-Driven Oncology Development.
Target Overview & Key Mutations
RET (Rearranged during Transfection) is a receptor tyrosine kinase with extracellular cadherin domains and an intracellular protein kinase domain (UniProt P07949). The V804L mutation is a gatekeeper mutation located in the kinase domain, resulting from a valine-to-leucine substitution at position 804. This mutation sterically hinders the binding of first-generation RET inhibitors (e.g., cabozantinib, vandetanib) and reduces sensitivity to selective inhibitors (selpercatinib, pralsetinib), leading to acquired resistance in NSCLC and medullary thyroid carcinoma. Additionally, RET V804L has been associated with Hirschsprung disease (HSCR1) in sporadic (dbSNP:rs1837067697), familial (dbSNP:rs76764689), and other forms (dbSNP:rs2132657920). The resolved target is RET (wild-type), with V804L as a key variant.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RET V804L drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Mutant Antigen | RET V804L Kinase Domain Protein (Active). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW confirmed. | View RET V804L Products |
| Wild-Type Control | RET (WT) Kinase Domain. Matched pair for selectivity profiling. Sequence Verified, >95% purity. | View RET Products |
| Gene Delivery | RET V804L Lentivirus Premade Particles. Full-length ORF with V804L mutation, HEK293T packaging, for stable cell line generation. | View RET V804L Products |
| Benchmark Reagents | Anti-RET recombinant mAb (detection grade) or Benchmark TKI control. For assay standardization (Western/Flow/IHC). | View RET V804L Products |
| Validator | RET siRNA Set. For knockdown verification and target-specificity validation in engineered cell lines. | View RET V804L Products |
| Related Target: KIF5B | Common fusion partner in NSCLC; used for fusion-mutant resistance modeling. | View KIF5B Products |
| Related Target: KDR | VEGFR2/KDR Kinase Domain; selectivity counter-screen for multi-kinase inhibitors. | View KDR Products |
| Related Target: MET | MET Kinase Domain/ECD-Fc; bypass resistance and combination target in NSCLC. | View MET Products |
| Related Target: ALK | ALK (L1196M) Gatekeeper Mutant; comparative resistance studies for kinase inhibitor design. | View ALK Products |
| Related Target: ROS1 | ROS1 Kinase Domain; off-target kinase screening within the RTK family. | View ROS1 Products |
Critical Assay Challenges and TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Gatekeeper Resistance Profiling (RET V804L vs WT) | Purified human RET V804L kinase domain (>95% purity, Endotoxin <1 EU/µg, Sequence Verified, Mass Spec Confirmed Identity). Matched wild-type RET kinase domain available for parallel IC50 determination. Active enzyme format with ATP-binding site integrity. |
| Selectivity Profiling (WT vs Mutant / Multi-kinase) | Panels of wild-type and mutant RET proteins, plus homologous kinases (KDR, MET, ALK, ROS1, FGFR1) for off-target counter-screens. Strict sequence verification and batch consistency. Endotoxin controlled. |
| Cellular Resistance Modeling & Assays | Lentivirus premade particles for stable cell line construction (Ba/F3 or NIH3T3). RET siRNA set for target-specificity validation. Endotoxin-controlled batches. |
| Lack of Controls / Reference Standards | Clinical benchmark compounds (e.g., selpercatinib, pralsetinib) available as positive controls. Matched wild-type proteins and lentivirus as reference standards. |
Live RET V804L R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RET therapeutics has transitioned from broad-spectrum multi-kinase inhibitors (cabozantinib, vandetanib) to highly selective RET inhibitors (selpercatinib, pralsetinib). However, the V804L gatekeeper mutation remains a pivotal preclinical benchmark for next-generation drug discovery. First-generation agents lose potency against V804L due to steric hindrance in the DFG-out conformation. The current clinical standard—selpercatinib and pralsetinib—utilizes Type I binding modes to retain activity, yet acquired resistance through solvent-front mutations (e.g., G810R/S) continues to drive demand for newer scaffolds, macrocyclic inhibitors, and RET-targeted PROTACs. The next wave of R&D is targeting mutant-selective degraders, brain-penetrant compounds for CNS metastases, and rational combination strategies with MET or EGFR pathway inhibitors. Key players include Eli Lilly, Blueprint Medicines/Roche, Bristol Myers Squibb (TPX-0046), Black Diamond Therapeutics, and preclinical biotechs developing PROTACs. As first-line selective therapies expand into adjuvant settings, the need for robust biochemical and cellular assays using sequence-verified RET V804L reagents has become indispensable.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Type I TKI | Eli Lilly, Blueprint Medicines / Roche | RET-fusion NSCLC, RET-mutant MTC | RET V804L vs WT inhibition profiling (high-purity mutant kinase protein) |
| Type II TKI (DFG-out) | Bristol Myers Squibb (TPX-0046), Black Diamond Therapeutics | Solid tumors (NSCLC, MTC) | DFG-out conformation assay (active RET V804L kinase domain) |
| Multi-kinase TKI | Exelixis, Sanofi | Advanced MTC, RCC | Selectivity panel (KDR, c-KIT kinase domains) |
| Next-gen Inhibitor / PROTAC | TP Therapeutics, Arvinas, Kymera (preclinical) | Resistant solid tumors, CNS metastases, refractory cancers | Cellular degradation or stable cell line assays (RET V804L lentivirus) |
Note: All product links are template placeholders (e.g., View RET V804L Products) to be replaced by the TarMart system.